RVC invests in Fund III of the UK company Epidarex Capital.

3 Jan 2019


To achieve Vision 2030 of the Kingdom of Saudi Arabia and the role of King Saud University in leveraging its capabilities by investing in knowledge-based companies locally and globally through its investment arm Riyadh Valley Company; RVC announces its participation in Fund III of the UK Epidarex Capital.
Epidarex is a transatlantic early stage investor in under‐ventured markets focusing on highly innovative companies within the Life Sciences & Healthcare industry, which consists of four subsectors: Pharmaceuticals, Biotechnology, Medical Devices and IT, Software & Services.
“Epidarex’s management team is very experienced in the venture capital market with strong industry knowledge in the Life Sciences sector” Says Dr. Khalid Alsaleh, CEO of RVC “also Epidarex’s global network includes investment professionals, scientists, industry executives, health practitioners, policy experts, regulatory advisors and business development leaders”.
He also added: “This investment opportunity falls under one of RVC’s main focus technologies in a step to enable RVC building a balanced local and global portfolio that achieves Kind Saud University’s goals and contributes to the enhancement of the economic competitiveness and development of the Kingdom of Saudi Arabia”.